8.1 Malignant Hyperthermia (MH) Pathophysiology, Protocol & Dantrolene Administration

Malignant Hyperthermia (MH) Pathophysiology, Protocol & Dantrolene Administration

Malignant Hyperthermia (MH) is a life-threatening, pharmacogenetic hypermetabolic crisis of skeletal muscle triggered in susceptible individuals by specific anesthetic agents. Without rapid recognition and aggressive intervention, MH carries a mortality rate exceeding 70%; however, structured protocols and prompt administration of dantrolene sodium have reduced modern mortality to under 5%. Perioperative registered nurses must master the pathophysiology, clinical indicators, emergency protocols, and pharmacologic management of MH.

---

Pathophysiology of Malignant Hyperthermia

MH is inherited primarily as an autosomal dominant trait with variable penetrance. The underlying defect in over 80% of susceptible patients involves a mutation in the RYR1 gene on chromosome 19q13.1, which encodes the ryanodine receptor type 1 calcium release channel in skeletal muscle sarcoplasmic reticulum. A secondary mutation involves the CACNA1S gene encoding the dihydropyridine receptor.

Upon exposure to triggering pharmacologic agents, the defective ryanodine receptor fails to close, resulting in an uncontrolled, massive flux of calcium ions ($Ca^{2+}$) from the sarcoplasmic reticulum into the myoplasm. This persistent intracellular calcium overload causes continuous binding of actin and myosin filaments, producing sustained, intense muscle contractions without neural stimulation.

This uncoupling of excitation-contraction coupling drives extreme hypermetabolism:

1. ATP Depletion & Lactic Acidosis: Myosin ATPase and sarcoplasmic reticulum $Ca^{2+}$-ATPase pumps work continuously to clear myoplasmic calcium and maintain contraction, consuming immense amounts of adenosine triphosphate (ATP). Aerobic metabolism increases exponentially, dramatically increasing oxygen consumption ($VO_2$) and carbon dioxide production ($VCO_2$). As oxygen supplies are exhausted, anaerobic metabolism leads to severe metabolic lactic acidosis.
2. Heat Generation: Intense muscular contraction and breakdown of high-energy phosphate bonds generate massive caloric energy, resulting in malignant hyperthermia.
3. Rhabdomyolysis & Cell Death: Depleted ATP stores compromise muscle cell membrane integrity, resulting in sarcolemmal destruction (rhabdomyolysis). Intracellular contents flood into the vascular system, spilling potassium ($K^+$), myoglobin, creatine kinase (CK), and phosphate into circulation.

---

Pharmacologic Triggers vs. Non-Triggering Agents

It is critical for perioperative personnel to distinguish between triggering agents and safe alternatives:

---

Clinical Manifestations & Diagnostic Progression

Recognizing the sequence of MH clinical signs is essential. A common exam trap is assuming high temperature is the first indicator; hyperthermia is actually a late manifestation.

Earliest & Most Sensitive Indicator

• Unexplained Hypercarbia: A rapidly rising end-tidal carbon dioxide ($ETCO_2$) level refractory to significant increases in minute ventilation is the earliest, most reliable indicator of MH. $ETCO_2$ values can double or triple within minutes.

Early to Intermediate Clinical Signs

• Unexplained Tachycardia: Sinus tachycardia occurs as the sympathetic nervous system responds to hypermetabolism, hypercarbia, and hypoxia.
• Masseter Muscle Rigidity (MMR): Severe spasm or trismus of the jaw muscles following succinylcholine administration. While mild jaw tightness can occur, forceful jaw clenching preventing endotracheal intubation is strongly diagnostic of MH.
• Generalized Muscle Rigidity: Board-like rigidity of the torso and limbs despite administration of muscle relaxants.
• Tachypnea & Cyanosis: Rapid breathing in non-paralyzed patients and skin mottling or duskiness due to extreme tissue oxygen extraction.
• Cardiac Dysrhythmias: Ventricular extrasystoles, ventricular tachycardia, or ventricular fibrillation driven by hyperkalemia and myocardial irritability.

Late Clinical Signs & Complications

• Hyperthermia: Rapidly escalating core body temperature, rising $1^\circ\text{C}$ to $2^\circ\text{C}$ every 5 minutes, frequently exceeding $41^\circ\text{C}$ ($105.8^\circ\text{F}$).
• Myoglobinuria: Dark red or tea-colored urine resulting from massive muscle breakdown. Myoglobin precipitates in renal tubules, risking acute tubular necrosis and acute kidney injury.
• Hyperkalemia & Acidosis: Serum potassium levels $>6.0\text{ mEq/L}$ and arterial blood gas demonstrating mixed severe respiratory and metabolic acidosis ($\text{pH} < 7.0$).
• Disseminated Intravascular Coagulation (DIC): Severe hyperthermia damages vascular endothelium, triggering systemic microvascular clotting, consumption of platelets and factors, and widespread hemorrhage.

---

Emergency Protocol & Dantrolene Administration

When MH is suspected, the surgical team must immediately execute the Malignant Hyperthermia Protocol:

[1. Call for Help & MH Cart] ➔ [2. Stop Triggers & Halter Surgery] ➔ [3. Hyperventilate 100% O2]
                                                                            │
[6. Post-Crisis Care & MHAUS] ◄── [5. Active Cooling & Supportive] ◄── [4. IV Dantrolene Bolus]

Step 1: Call for Help & Request MH Cart

Call out clearly for assistance and direct a team member to retrieve the dedicated MH Emergency Cart. Declare the emergency to all OR personnel.

Step 2: Discontinue Triggering Agents & Wrap Up Surgery

Immediately turn off all volatile anesthetic vaporizers and discontinue succinylcholine. Inform the surgeon to halt the procedure or conclude surgery as rapidly as possible.

Step 3: Hyperventilate with 100% Oxygen

Administer 100% pure oxygen at high flow rates ($10\text{--}15\text{ L/min}$) using maximum minute ventilation to flush out carbon dioxide and volatile gases. Insert activated charcoal filters into the breathing circuit limbs if available; do not delay ventilation to change the circuit.

Step 4: Administer IV Dantrolene Sodium

Dantrolene sodium is a specific ryanodine receptor antagonist that binds to the RYR1 channel, blocking sarcoplasmic calcium release without affecting cardiac muscle contraction.

• Initial Bolus Dose: 2.5 mg/kg IV rapidly. Repeat 2.5 mg/kg boluses every 5–10 minutes until hypercarbia, rigidity, and tachycardia subside. Cumulative doses may exceed 10 mg/kg in severe crises.
• Formulation & Reconstitution:
  • Classic Dantrolene (Dantrium / Revonto): Formulated in 20 mg vials containing 3 grams of mannitol. Each 20 mg vial must be reconstituted with 60 mL of sterile water for injection without a bacteriostatic agent. Warm sterile water accelerates dissolution. Note: An adult requiring 2.5 mg/kg (e.g., 70 kg = 175 mg) requires reconstitution of 9 vials with 540 mL of fluid.
  • Nanoparticle Dantrolene (Ryanodex): Formulated in 250 mg vials containing 125 mg mannitol. Reconstituted with only 5 mL of sterile water for injection. Dissolves in under 30 seconds, delivering an initial dose in a single syringe.

Step 5: Active Cooling & Supportive Interventions

• Cooling Protocol: Administer cold 0.9% normal saline ($15\text{ mL/kg IV}$ over 10 minutes). Apply ice packs to axillae, groin, and neck. Perform cold saline lavage of stomach, bladder, or open peritoneal cavity. Stop active cooling when core temperature reaches $38.5^\circ\text{C}$ ($101.3^\circ\text{F}$) to prevent hypothermia overshoot.
• Hyperkalemia Treatment: Administer regular insulin (10 units IV) alongside 50% dextrose ($50\text{ mL IV}$). Administer calcium chloride ($10\text{ mg/kg}$ or 1 gram IV) for cardiac membrane stabilization in severe hyperkalemia. Administer sodium bicarbonate ($1\text{--}2\text{ mEq/kg IV}$) for severe metabolic acidosis.
• Renal Protection: Maintain urine output $>2\text{ mL/kg/hr}$ using IV hydration, furosemide, and mannitol. Monitor for myoglobinuria.

Step 6: Post-Crisis Care & MHAUS Consultation

Transfer the patient to an ICU for continuous monitoring for at least 24–48 hours. Recrudescence (MH recurrence) occurs in up to 25% of patients. Administer maintenance dantrolene at $1\text{ mg/kg IV}$ every 4–6 hours or $0.25\text{ mg/kg/hr}$ continuous infusion. Contact the MHAUS 24/7 Hotline at 1-800-MH-HYPER (1-800-644-9737) for expert clinical consultation.

---

Key Exam Traps & Clinical Pitfalls

⚠️ Exam Trap: Never reconstitute dantrolene with 0.9% normal saline, D5W, or bacteriostatic water—these solutions cause solute precipitation.

⚠️ Exam Trap: Never co-administer calcium channel blockers (e.g., verapamil, diltiazem) with dantrolene. Combined administration causes severe hyperkalemia, profound myocardial depression, and cardiovascular collapse.

⚠️ Exam Trap: Avoid Lactated Ringer's solution for cooling or resuscitation during MH, as it contains exogenous potassium ($4\text{ mEq/L}$) and lactate, worsening hyperkalemia and metabolic acidosis.